GMV 0.00% 3.9¢ g medical innovations holdings limited

GMV - Fundamental Analysis, page-7

  1. 6,165 Posts.
    lightbulb Created with Sketch. 2345
    Minor adjustments:

    Boletong, U$67.5M (not $65m),
    =A$93.5M
    About 500,000 prizma, my estimate,
    =U$135
    each prizma, B2B price,

    plus
    B.Silverlake,
    100,000 units, at $135
    = U$13.5m, for Year 1.
    = A$18.5M

    Total China deals
    = A$112 million, Year 1.

    +
    Taiwan
    +
    USA IDTF etc
    =

    SOI
    Total shares & options
    408.5m + 13.5m (Gem)
    = 422m
    + 28 options ( est)
    =450m
    ,

    Mkt Cap
    450m × 20c = A$90m
    v
    China deals, $112m

    Rerating is in initial iceberg stage.
    Lets hope all LTHS will hold on till they make 2-3 bags, whatever your av buy price, before unloadinga small portion.

    Tight register
    422m shares,
    80% is in Top 20 (incl yacov 22%, Gem 3%)
    10 to 15% is in LTHs, Top 21-100 shh
    Only 5% are in free float,
    20m shares, for newcomers, to bid up.

    ps,
    My opinions and estimates only.
    You can agree or disagree.
    Seek professional investment advice before punting in spec startups.



    Last edited by Glyco: 20/01/20
 
watchlist Created with Sketch. Add GMV (ASX) to my watchlist

Currently unlisted public company.

arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.